论文部分内容阅读
目的初步探讨贵州侗族人类白细胞抗原(HLA)-DRB1基因多态性与拉米夫定抗乙型肝炎病毒近期疗效的相关性。方法选取贵州省侗族慢性乙型肝炎患者90例,予口服拉米夫定每日100mg,疗程24周;分别于基线、12周、24周检测HBV DNA及ALT,据治疗24周后HBV DNA及ALT变化将患者分为有效组(完全应答及部分应答)和无效组(无应答);测定两组受试人群的HLA-DRB1基因型;统计学处理HLA-DRB1基因型在两组之间是否存在差异。结果 HLA-D刘琴RB1*07、*14基因频率在拉米夫定治疗无效组明显高于有效组(HLA-DRB1*07:12.5%VS2.31%,χ2=10.097,P<0.05,OR=0.300;HLA-DRB1*14:18.75%VS 9.23%,χ2=7.049,P<0.05 OR=0.149),其他等位基因频率在两组间差异无显著性。结论推测拉米夫定抗病毒疗效与HLA-DRB1存在一定相关性,携带HLA-DRB1*07、*14基因患者预示拉米夫定抗病毒疗效不佳。
Objective To investigate the association between HLA-DRB1 polymorphism in Guizhou Dong people and the short-term efficacy of lamivudine against hepatitis B virus (HBV). Methods Ninety patients with chronic hepatitis B in Dong ethnic group of Guizhou Province were enrolled in this study. 100 mg lamivudine was given daily for 24 weeks. HBV DNA and ALT were detected at baseline, 12 weeks and 24 weeks respectively. The changes of ALT divided the patients into effective group (complete response and partial response) and ineffective group (no response); determined the HLA-DRB1 genotype of two groups; statistically analyzed whether HLA-DRB1 genotype between the two groups has a difference. Results HLA-D Liu Qin RB1 * 07, * 14 gene frequency in the lamivudine treatment group was significantly higher than the effective group (HLA-DRB1 * 07: 12.5% VS2.31%, χ2 = 10.097, P <0.05, OR = 0.300; HLA-DRB1 * 14: 18.75% VS 9.23%, χ2 = 7.049, P <0.05 OR = 0.149). There was no significant difference in other alleles between the two groups. Conclusions It is speculated that there is a certain correlation between the efficacy of lamivudine antiviral therapy and HLA-DRB1. The patients with HLA-DRB1 * 07 and * 14 genes predicted the poor efficacy of lamivudine antiviral therapy.